Mirae Asset Global Investments Co. Ltd. has recently revealed that it lessened its position in shares of Sangamo Therapeutics, Inc., ...
On May 10, 2023, Truist Securities analyst Nicole Germino announced a Buy rating for Sangamo Therapeutics (NASDAQ: SGMO) while reducing ...
Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a leading biopharmaceutical company, has been making waves in the pharmaceutical community as of late. With ...
Los Angeles Capital Management LLC, a prominent institutional investor, has recently decreased its stake in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) by ...
The biopharmaceutical industry is one of the most complex sectors of our economy, with companies constantly competing to discover and ...
Sangamo Therapeutics Inc. has recently unveiled a major restructuring plan that is expected to save the company approximately $31 million, ...
As of April 14, 2023, Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has received a "Moderate Buy" consensus rating from six ratings firms ...
Sangamo Therapeutics (NASDAQ: SGMO) has seen a decrease in its average price target by 33.95% from the previous quarter, according ...
San Francisco-based biotech company, Sangamo Therapeutics, Inc. (NASDAQ: SGMO), has announced in an 8-K filing that it is engaging in ...